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The National Institute of Allergy and Infectious Dis-
eases (NIAID), part of the National Institutes of Health
(NIH), recently awarded 14 contracts to fund the
Large-Scale Antibody and T Cell Epitope Discovery
Program. This initiative is designed to identify immune
epitopes from selected infectious agents utilizing com-
plementary methods for epitope discovery. NIAID will
make information on each newly identified epitope
freely available to scientists worldwide through the
Immune Epitope Database and Analysis Resource
(IEDB), currently under development. On October 12–
14, 2004, representatives of NIAID met in San Diego,
California, with a group of investigators from various
research institutions to discuss progress and plans
for the large-scale epitope discovery projects and for
the establishment of the IEDB. It is anticipated that
these initiatives will establish detailed maps of im-
mune reactions toward several important complex pa-
thogens, which in turn will foster development of new
diagnostic, immune-based therapeutic, and vaccine
programs. Herein is an account of the meeting and
its results.
Introduction
Recent times have seen an explosion of knowledge re-
lated to the genetic and protein structures of microbes
and complex organisms alike. This genomics and pro-
teomics era is now followed by the development of
more-specialized collections of data relating to particu-
lar aspects of cell biology and immunology. In this
context, the immunome can be defined as the detailed
map of immune reactions of a given host interacting
with a foreign antigen, and immunomics can be defined
as the study of immunomes.
In the aftermath of the 9/11 attacks, federal support
of research in the area of biodefense has dramatically
increased. A key element of the National Institute of
Allergy and Infectious Diseases (NIAID), part of the Na-
tional Institutes of Health (NIH), Biodefense Research
program to address the potential threat posed by cate-
gory A–C pathogens (as listed at http://www2.niaid.nih.
gov/biodefense/bandc_priority.htm) is the generation
and gathering of accurate scientific information related
to these dangerous agents. It is anticipated that these
data will in turn lead to the generation of new research
tools and to the discovery and development of new di-
agnostics, vaccines, and therapeutics, for emerging*Correspondence: alex@liai.organd reemerging pathogens, including potential bioter-
rorism agents. Accordingly, an aggressive program has
been initiated to support the large-scale identification
of immune epitopes derived from NIAID category A–C pa-
thogens (Large-Scale Antibody and T cell Epitope Dis-
covery Program). The same programmatic area has
sponsored the creation of a national database, the Im-
mune Epitope Database and Analysis Resource (IEDB),
to house existing epitope data as well as data resulting
from these novel discovery efforts. It is anticipated that
these data will be made freely available to the scientific
community. The IEDB will also house a general analysis
resource, which will host bioinformatics tools devel-
oped to assist in epitope prediction and data analysis,
and facilitate vaccine development (http://www.niaid.
nih.gov/contract/archive/rfp0331.pdf and http://www.
niaid.nih.gov/contract/archive/RFP0343-0.pdf). A dia-
gram illustrating the major components of the IEDB and
the Large-Scale Antibody and T cell Epitope Discovery
Program is shown in Figure 1.
The rationale for establishing both initiatives stems
from the realization that one of the main impediments
to accurate and rapid development of vaccines and di-
agnostics for Category A–C pathogens is the scarcity
of basic information relating to the epitopes recognized
by adaptive immune responses. Indeed, very little infor-
mation exists relating to the molecular details of im-
mune responses to most of these pathogens. This pau-
city of information hampers the monitoring of immune
responses themselves either in the course of natural
infection or in response to experimental vaccines. This
lack of knowledge also hinders basic investigations fo-
cused on pathogen/host interactions, studies to deter-
mine potential immune evasion or escape mechanisms
of a given pathogen, and the correlation of vaccination
with protective immunity.
Representatives from NIAID met with investigators
involved in the creation of the IEDB and those recipi-
ents of contracts through the Large-Scale Antibody and
T cell Epitope Discovery Program on October 12–14,
2004, in San Diego, CA. The three-day meeting began
with a presentation detailing the creation of the IEDB,
its objectives, and its planned functionality at launch in
2005. This initial presentation was followed by a series
of presentations from representatives of the various in-
stitutions who had been awarded contracts to work on
epitope identification and collaborate in populating
the IEDB.
The Immune Epitope Database
Started in December 2003, the IEDB will be the world’s
largest database specifically devoted to immune epi-
tope data and is expected to facilitate explorations of
immunity to infectious agents as well as immune-medi-
ated disorders. The database will allow researchers
around the globe to quickly access key information on
immune responses and to share and analyze data in an
unprecedented manner. It is expected to be publicly
available in late 2005 and will include antibody and T
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156Figure 1. Integration of Various Components
of the Large-Scale Antibody and T cell Epi-
tope Discovery Program and IEDB
The IEDB will include data that is collected
from existing databases, curation from the
literature and patent sources by IEDB staff,
and direct submissions to the database.
Among the most important and substantial
submission data sets will be those from each
of the Large-Scale Antibody and T cell Epi-
tope Discovery Program research teams
(see Table 1 for more detail). Once submitted
and further annotated, the data can be re-
trieved by users at large over the Internet
using a standard web browser. The results of
their queries can be exported and/or further
analyzed online utilizing tools provided in the
analysis resources that are directly hosted at
or linked to the IEDB.cell epitopes from infectious pathogens, as well as ex- t
tperimental and self-antigens. A key element in the
nation’s battle against infectious diseases, and in line t
Iwith federal research goals, the database will place
particular emphasis on NIAID Category A–C pathogens, n
bsuch as anthrax, smallpox, West Nile virus, influenza,
and SARS. Detailed information from humans, nonhu- m
man primates, rodents, and any species for which de-
tailed immune response information is available will be d
Sincluded. In terms of scale, the IEDB structure will allow
the inclusion of a large number of records (several hun- s
udred thousand) and accommodate further growth (e.g.,
from the large-scale epitope discovery programs). f
MExtensive annotation will allow context representation
coupled with extensive use of flexible query strategies, d
cwhich will allow users to customize searches to the de-
sired level of stringency and to include or to exclude i
tvarious types of information, as described in more de-
tail below. At the conference, the progress to date on M
tthe design of the database was presented. Research-
ers from the La Jolla Institute for Allergy and Immunol- M
gogy (LIAI), which is in charge of its development, sought
feedback from attendees to ensure that the database t
gwill be responsive to the needs of the scientific com-
munity. e
p
nProgress in the Development of the IEDB
Perhaps the two most crucial issues in the design of e
tthe Immune Epitope Database are the definition of what
constitutes an epitope and the development of an inno- s
ovative general conceptual framework that dictates how
epitope data can be represented systematically. These o
aissues were actively debated throughout the workshop.
An epitope can be defined as the chemical structure o
crecognized by antigen-specific receptors of the immune
system (antibodies and/or T cell receptors (TCRs). How- t
aever, it has been noted that, over the course of the last
20 years, large amounts of data have accumulated re- S
olating to molecules that can bind to specific MHC mole-
cules. In addition, data have been generated relating to b
astructures that are naturally bound by MHC molecules.
Taken together, these data have defined the chemical m
sspecificity of MHC molecules and constitute the foun-
dation of methods to predict and identify T cell epi- uopes. MHC binding does not guarantee, per se, that
he resulting complex will engage specific TCRs and
hereby meet the definition of an epitope. However, the
EDB will also include data relating to MHC binding and
atural MHC ligands because compounds capable of
inding MHC molecules have the potential of being im-
unogenic or antigenic for T cells.
The logical design of the database and how epitope
ata will be represented were discussed by Alessandro
ette and Stephen Wilson (LIAI, San Diego, CA). Intrin-
ic epitope features included in the IEDB are the molec-
lar structure of the epitope, binding affinity for dif-
erent MHC receptors or antibody molecules, affinity of
HC/epitope complexes for antibodies and TCRs of
efined sequence, and the phylogenetic origin and
onservation of the epitope structure in related organ-
sms. Available 3-D structures of antibody epitopes, an-
ibody/epitope complexes, epitope/MHC, and epitope/
HC/TCR complexes will also be included. These fea-
ures are unequivocally specified with relative ease.
ost importantly, they are singularly associated with a
iven epitope structure or epitope/receptor combina-
ion. Other features, such as antigenicity and immuno-
enicity, are not intrinsically associated with a given
pitope or structure but rather are highly context de-
endent. To meaningfully specify antigenicity or immu-
ogenicity, information regarding the structure of the
pitope alone is not sufficient. Other variables relating
o the interaction of such structures with the immune
ystem must also be represented, including the species
f the host (or vaccine recipient) in which the response
ccurs, the dose and route of administration, and the
ssay utilized to measure responses. The logical design
f the database, which captures both intrinsic and
ontext-dependent information, is well advanced. A de-
ailed Entity Relationship Diagram is already available,
nd a semiformal ontology is now under development.
pecific examples of how the data might be accessed
r viewed are not yet available to the public, but as they
ecome available, will be posted on the IEDB website
t www.immuneepitope.org. While still in final develop-
ent, the web-based interface has been designed to
upport both simple and highly complex searches
sing a query-by-example approach, which then allows
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157users to export results or analyze those results further
with online tools.
In terms of populating the database, the IEDB staff
adopted from the outset the general guideline and phi-
losophy that it is not the function or prerogative of the
IEDB to decide what is good or bad data. Rather the
job of the IEDB team is to provide adequate information
to allow its users (the scientific community) to evaluate
the results for themselves. This philosophy is aligned
with those embraced by other first line generalist data-
bases (such as PubMed) that do not select data for
inclusion on the basis of some predetermined criteria
of worthiness, but rather strive to provide the user with
comprehensive access to available data, together with
flexible query and reporting strategies. This philosophy
was somewhat controversial and not universally ac-
cepted, as some attendees believed that data should
be prefiltered to insure data consistency and homo-
geneity. A possibility discussed by the participants was
to include all data but specifically flag data generated
by widely accepted and validated procedures and
methodologies.
The IEDB will utilize existing journal articles and pat-
ent filings as one of its three main categories for data
source. It is currently estimated that about 50,000 pa-
pers and patents may be relevant. Data from direct
submission will constitute the second category for data
source to the database (e.g., from the large-scale epi-
tope discovery contracts, as well as other investiga-
tors), and the final category of data source is from other
epitope databases who are willing to contribute to the
effort.
Development of an Epitope Analysis Resource
As mentioned above, it is envisioned that the IEDB will
also host an Epitope Analysis Resource. The resource
will essentially be composed of a library of tools and
methods, developed by the scientific community as
well as IEDB project staff, hosted directly on the IEDB
website or linked from the IEDB website. Objective
methods for tool evaluation and reevaluation will be a
key point of development. Two main types of tools will
be hosted—analysis tools and predictive tools. Exam-
ples of analytical tools include those designed to pro-
ject vaccine population coverage, to predict the degree
of population coverage afforded by a given epitope or
epitope set in different ethnicities, and to assess the
degree of conservancy of a given epitope within a data-
base of different sequences. Tools specifically de-
signed to visualize and analyze epitope 3D structures
will also be provided.
The analysis resource will also include predictive
tools and methods. In the context of antibody epitopes,
standard methods such as hydrophobicity analysis,
solvent accessibility, and thermal mobility tools, as well
as tools to predict epitopes’ 3D structures, will be pro-
vided. In the context of T cell epitopes, tools and meth-
ods specifically designed to predict cellular processing
and binding to MHC class I and class II molecules will
be made available. Finally, it is envisioned that the large
mass of contextual data present in the database might
also result in the development of novel methods to pre-
dict T cell and antibody epitopes. There is broad con-sensus that the development of a large scale initiative
for epitope mapping, and associated database will al-
low the scientific community to greatly improve the
breadth and efficiency of existing predictive tools re-
lated to immune epitopes and immune responses.
Availability of a large library of bioinformatics tools to
predict and analyze immune response data will allow
the general immunologist to perform customized analy-
sis and to assist them in basic investigations as well
as in the evaluation and design of new diagnostic and
vaccine strategies.
Prediction and Validation of MHC
Class I T Cell Epitopes
After the in-depth discussion of the IEDB project, the
focus of the presentations and discussion shifted to the
various research teams working on the Large-Scale An-
tibody and T Cell Epitope Discovery Program. A table
summarizing the fourteen teams of investigators and
their respective discovery methods can be found in Ta-
ble 1. Several different epitope discovery groups are
currently working on developing and refining methods
to predict and identify MHC class I T cell epitopes. The
rational development of predictive Artificial Neural Net-
works through an iterative “Query by Committee”-
guided approach was described by Søren Buus from
the Institute for Medical Microbiology & Immunology
(IMMI) at the University of Copenhagen. This approach
is based on the concept that computational tools,
which can predict the outcome of the most important
events involved in defining T cell epitopes, should be
developed and integrated to yield an overall prediction
of the these events. These tools should have a capacity
that enables them to handle whole genome/proteome
data both in terms of accuracy and computational re-
sources required. According to Buus, publicly available
predictive algorithms have thus far resulted in more or
less arbitrary scoring of epitopes, and they have been
unable to handle the massive amounts of whole ge-
nomes and proteome data, limiting the integration of
relevant predictions and severely hampering the full ex-
ploitation of the steadily growing body of genome and
proteome data. The primary goal of this group is to de-
velop computational tools that accurately can predict
peptide binding to HLA class I (HLA-I) molecules. Of
the more than 1100 different HLA-I haplotypes in the
human population, a subset that gives maximum cover-
age and represents the diversity of HLA-I molecules is
being selected. Highly efficient and accurate prediction
tools will be developed for these HLA-I molecules.
Similarly, the prediction and validation of CTL epi-
topes is the main goal of the project presented by Ole
Lund from the Center for Biological Sequence Analysis
(CBS) at the Technical University of Denmark. This pro-
ject proposes to develop improved methods to predict
cytotoxic T cell (CTL) epitopes and use these methods
to scan 15 different pathogens from the NIAID A-C list
agents of bioterrorism. For each of the 15 pathogens,
the top 15 CTL epitopes for each of 14 different HLA
alleles will be predicted. These 3150 peptides will be
produced synthetically, and their binding affinity to the
relevant HLA molecules will be tested. For selected pa-
thogens (Influenza, Smallpox vaccine, and tuberculosis
Immunity
158Table 1. Summary of Discovery Methods and Laboratories Involved in the Large-Scale Antibody and T Cell Epitope Discovery Program
Epitope
Typesa Epitope Sources Main Discovery Method(s) Institutionb Investigatorsb
B Clostridium botulinum Phage display TSRI Kim Janda
neurotoxins
T-I Various Development of predictive algorithms for Univ. of Soren Buus (UC)
MHC class I binding Copenhagen
T-I 15 different A-C pathogens Predictive algorithms and MHC class I Technical Univ. Ole Lund (DTU), Morten
binding assays of Denmark Nielsen (DTU), Claus
(DTU) Lundegaard (DTU), Mikkel
Harndahl (UC), Soren Buus
(UC), Mogens Claesson
(UC), Soren Brunak (DTU)
T-I Ebola virus and MHC class I binding assays Duke Univ. Kent Weinhold (Duke),
Mycobacterium Georgia Tomaras (Duke),
tuberculosis Scott Pruitt (Duke), Tina
Kuus-Reichel (Beckman
Coulter)
T-I Influenza virus, West Nile Elution and sequencing of naturally Univ. of William Hildebrand
virus and Coxiella processed peptides Oklahoma
burnetii
T-I Vaccinia virus Elution and sequencing of naturally Vanderbilt Univ. Sebastian Joyce
processed peptides
T-I, T-II Arenaviruses HLA transgenic mice, and MHC binding LIAI Alessandro Sette (LIAI)
assays Michael Buchmeier (TSRI)
Jason Botten (TSRI)
T-I, T-II Flavi, arena, hanta, Predictive algorithms, HLA transgenic mice Johns Hopkins J. Thomas August (JHU),
hepatitis A, yellow fever and human clinical cohorts Univ. Vladimir Brusic (I2R),
and rabies viruses Romulo Maciel (FIOCRUZ),
Ernesto Marques
(FIOCRUZ)
T-I, T-II Tularemia bacterium Bacterial expression of random genomic Univ. of North Jeffrey Frelinger (UNC), Tom
fragments, T cell hybridoma readout Carolina Kawula (UNC), Lucinda
Hensely (UNC), John
Frelinger (U. Rochester)
T-I, T-II Vaccinia virus HLA transgenic mice, MHC binding assays LIAI Alessandro Sette
and PBMCs from immunized donors
T-I, T-II Vaccinia virus T-cell clones derived from immunized TPIMS Clemencia Pinilla
donors and combinatorial peptide libraries
T-I, T-NC Mycobacterium Identification and cloning of pathogen Oregon Health & David Lewinsohn
tuberculosis specific CD8+ T-cells Science U.
T-II Bacillus anthracis and HLA transgenic mice, and MHC binding Imperial College, D. Altmann (ICL), S.
Yersinia pestis assays London, Sriskandan (ICL), J.
England Robinson (U. Newcastle), D.
Williamson (Dstl, Porton
Down), L. Baillie (UMBI)
T-II Influenza A and B viruses, Tetramer Guided Epitope Mapping Benaroya William Kwok
Clostridium tetani, and Research Inst.
Bacillus anthracis at Virginia
Mason
aT-I = MHC class I restricted T-cell epitopes; T-II= MHC class I restricted T-cell epitopes; T-NC = nonclassically restricted T-cell epitopes; and
B = B-cell / antibody epitopes.
bTSRI = The Scripps Research Institute, La Jolla, CA; LIAI = La Jolla Institute for Allergy and Immunology, San Diego, CA; TPIMS = Torrey
Pines Institute for Molecular Studies, San Diego, CA; I2R = Institute for Infocomm Research, Singapore; FIOCRUZ = Oswaldo Cruz Foundation,
Brazil; and UMBI = University of Maryland Biotechnology Institute.vaccine, BCG), it will be tested whether cytotoxic T g
tcells from preselected immune blood donors can react
to the selected peptides. The presenter pointed out l
mthat because of the close collaboration between bioin-
formaticians and laboratory scientists, the few most p
blikely epitope candidates can be rapidly selected using
computer predictions, and the relatively costly labora- e
Atory experiments can then be performed for a small
subset of possible epitopes. w
dT cell epitope identification based on a novel solid
phase MHC class I monomer binding platform was de- m
mscribed by Kent Weinhold of Duke University. Thisroup will adopt an approach to epitope identification
hat measures the binding affinity and off-rates of over-
apping 9-mer peptides to MHC class I allelic mono-
ers. The test peptides are contained within a defined
reselected target region of microorganisms responsi-
le for various emerging/reemerging infectious dis-
ases. Eight different MHC class I monomers (A1, A2,
3, A11, A24, B7, B8, and B15) are presently available
ith additional allelic reagents in development. Indivi-
ual peptides will be scored based on their perfor-
ance characteristics, and those above a predeter-
ined threshold score will be further evaluated in the
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159context of a human dendritic cell-based stimulation
platform to assess in vitro immunogenicity. Lastly, the
immunogenicity of individual peptides will be further
assessed by measuring epitope recognition by CD8+ T
cells from either vaccine recipients or patients who
have recovered from active infection. These studies are
focused on defined targets within early and immediate
early gene products of poxviruses, the Ebola virus gly-
coprotein, and proteins expressed by multidrug-resis-
tant Mycobacterium tuberculosis (Mtb).
The project directed by William Hildebrand at the
University of Oklahoma is also aimed at directly map-
ping and characterizing T cell epitopes that arise during
infection with Category A–C bioterrorism agents. The
approach is based on a comprehensive, high-through-
put epitope-identification strategy that combines mass
spectrometry and Edman sequencing to identify pep-
tides presented on infected cells. The epitopes unique
to infected cells are then validated in a number of man-
ners, including T cell immunogenicity, biochemical and
molecular analyses, and cell-surface staining of epi-
tope/MHC complexes.
David Lewinsohn of the Oregon Health and Sciences
University described a method for mapping Mtb-spe-
cific human CD8 T cell antigens and epitopes, based on
definition of the dominant classically and nonclassically
restricted CD8+ T cell antigens, followed by the defini-
tion of the corresponding minimal T cell epitopes. Fi-
nally, these investigators also propose to define in TB-
endemic populations the clinical utility of these anti-
gens and epitopes. To ensure complete coverage of the
Mtb genome, three separate but complementary ap-
proaches to identifying immunodominant antigens will
be used. First, peptide pools derived from likely Mtb
antigens will be used to define a set of commonly and/
or strongly recognized CD8+ T cell antigens. Second,
the antigen recognized by Mtb-specific T cell clones
will be identified using either peptide pools, or expres-
sion cloning. Finally, where possible, antigens will be
directly purified from the cell-wall fraction of Mtb.
Identification of Antibody Epitopes and T Cell
Epitopes Restricted by MHC Class II Molecules
Several groups are engaged in developing approaches
to map antibody epitopes and MHC class II restricted
epitopes. Kim Janda, from The Scripps Research Insti-
tute (TSRI), presented an overview of his studies using
human antibodies for epitope mapping and neutraliza-
tion of botulinum neurotoxins (BoNTs). This research is
focused on three main aspects: (1) Selecting human
mAbs against BoNT types A, B, and E using a novel
phage-display technology; (2) Identifying epitopes for
these human mAbs using antigen-fragment libraries, a
random linear peptide library, and a random cyclic pep-
tide library; and (3) Validating antigenicity and immuno-
genicity of defined mAb epitopes via in vitro cell-based
assay and an in vivo mouse bioassay.
William Kwok (Benaroya Research Institute at Virginia
Mason) reported an original approach for the identifica-
tion of CD4+ T cell epitopes named tetramer-guided
epitope mapping (TGEM) of class II multimers through
exogenous peptide loading onto empty class II mole-
cules. In preliminary studies the TGEM methodologyled to identify CD4+ T cell epitopes directed against
tetanus toxoid derived from Clostridium tetani and
hemagglutinin of influenza virus type A. A multiplexing
approach was also developed that allowed the identifi-
cation of epitopes restricted by multiple HLA alleles in
a single experimental setup. The TGEM approach will
be used to identify CD4+ T cell antigenic epitopes from
Clostridium tetani, Bacillus anthracis, and influenza
viruses type A and B.
Daniel Altmann and his UK colleagues plan to map
CD4 epitopes from anthrax and yersinia. CD4 T cell epi-
topes relevant to humans for the principal vaccine anti-
gens of B. anthracis and Y. pestis will be mapped using
mice transgenic for common HLA class II alleles. Paral-
lel studies will compare CD4 T cell peptide recognition
after priming with peptides, recombinant proteins, or
live infection, to determine whether infection skews
epitope generation through APC impairment. Epitopes
will then be tested for binding across a wide range of
HLA alleles to identify those with likely broad applica-
bility. Antigen processing studies will identify epitopes
that are most readily and rapidly be generated by APC.
In particular, candidate epitopes identified from the
anthrax studies will be used to screen the responses of
vaccine recipients and immune individuals in southern
Turkey recovering from live anthrax infection. Epitopes
that appear to be strong candidates from the preceding
studies will be validated by incorporation into vaccine
constructs for in vivo protection studies using an HLA
transgenic mouse susceptibility model.
In general, it is envisioned that the area of identifica-
tion and prediction of antibody epitopes is a key area
that will see significant advances in the next decade.
Historically this area has been technically most chal-
lenging because of the uncertainty in the register uti-
lized by epitopes binding to class II MHC molecules,
and because of the complicating influence of 3D
requirements on the binding of antibodies to conforma-
tionally sensitive and discontinuous epitopes. However,
the development of new technologies, the availability
of large data sets to assist in predictive methods, and
the constant advances in the availability and prediction
of 3D structures are all widely predicted to impact the
field in a dramatic and positive way.
Projects Aiming at the Simultaneous Identification
of MHC Class I- and II-Restricted T Cell Epitopes
Jason Botten (TSRI) presented a study resulting from
the collaboration of the laboratory of Michael Buch-
meier (TSRI) and Alessandro Sette (LIAI) aimed at the
discovery and validation of both cytotoxic and helper T
cell epitopes presented by HLA class I and class II MHC
molecules derived from prevalent arenaviruses (Junin,
Guanarito, Sabia, Machupo, Lassa, LCMV and White-
water arroyo) causing disease in humans. After the
identification of human class I and class II restricted
epitopes derived from these 7 arenaviruses, a recombi-
nant vaccinia virus incorporating these determinants
will be tested in HLA-transgenic mice. Epitopes re-
stricted by common murine and macaque MHC mole-
cules will also be identified. It is anticipated that these
studies will lead to the development of tools for diag-
nostic evaluations and new vaccine development,
Immunity
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dsource. After annotation of 523 sequences extracted
from the NCBI database, 333 unique arenavirus se- e
rquences were selected for epitope discovery studies.
In pilot experiments, viral gene sequences of Lassa p
lJosiah and Lassa GA-391 were screened for HLA-A2,
-A3, and -B7 supertype epitopes. Thus far, 19 A2 (n = d
b33) and 4 A3 (n = 12) potential epitopes were found to
be immunogenic in the transgenic mouse system. w
vAn epitope discovery program applied to human clin-
ical cohorts and epitope-based vaccine design was s
cpresented by J. Thomas August of Johns Hopkins Uni-
versity. The structure of this program encompasses f
useveral different components: (1) A genome-wide com-
putational immune epitope discovery (V. Brusic, Insti- i
tute for Infocomm Research, Singapore); (2) Human
clinical cohorts for flaviviruses, arenavirus, hantavirus, A
Chepatitis A, yellow fever, and rabies (R. Maciel, FIO-
CRUZ, Brazil); (3) Ex vivo analysis of epitope-specific T v
(cell responses of clinical cohorts (E. Marques, Aggeu
Magalhaes, Research Center, FIOCRUZ; and (4) Epi- t
ctope validation in vitro and with HLA transgenic mice
and epitope-based vaccine design (T. August, Johns d
THopkins University). This approach focuses on the dis-
covery of epitopic hot spots of multiple promiscuous m
tepitopes. These hot spots will be incorporated into ge-
netic vaccines targeted to specific cellular compart- s
sments. Epitope processing and presentation will be an-
alyzed in HLA transgenic mice and mouse model p
Asystems.
The high-throughput identification of bacterial epi- m
ttopes by T cell antigen discovery (TCAD) and its appli-
cation to Francisella tularensis was described by Jef- t
frey Frelinger (University of North Carolina) and
colleagues. This method utilizes a combination of bac- i
pterial expression of random genomic fragments cou-
pled with a mechanized method of recombinant protein t
wpurification and a highly sensitive readout using T cell
hybridomas. This combination allows rapid throughput c
vand prescreens the epitopes identified as authentic T
cell epitopes. In this system, DHFR fusion proteins are c
mpurified and coupled to beads. These beads are fed to
APC and tested for their ability to stimulate T cell hy- a
tbrids derived from Francisella tularensis immunized an-
imals. To date, the investigators have demonstrated h
their ability to screen large numbers of hybrids using
the expression technology using libraries encoding M
variants of a T cell epitope of Prostate Specific Antigen I
(PSA). They have also prepared an initial expression li- o
brary derived from Francisella tularensis strain LVS. Fi- s
nally they have prepared a library of over 200 Franci- r
sella tularensis-specific T cell hybrids prepared from i
mice immunized with Francisella tularensis extracts. a
l
IStudies Aimed at Defining the Response to Vaccinia
Virus after Vaccination against Smallpox h
dThe two preceding sections related to projects focusing
on a given epitope type. In this final section, we will O
tpresent an account of several different groups all
targeting the same pathogen (Poxviruses) to exemplify a
show the Large-Scale Antibody and T Cell Epitope Dis-
covery Program will generate complementary, multidis- r
tciplinary data relating to a given pathogen. The focusf the research presented by Sebastian Joyce of Van-
erbilt University is to identify and characterize CTL
pitopes common between vaccinia and variola viruses
estricted by members of six different HLA class I su-
ertypes that account for >99% of the HLA class I al-
elic products. It is predicted that one or a few immuno-
ominant HLA-restricted CTL epitope(s) is presented
y each HLA class I supertype. The proposed approach
ill be to determine the amino acid sequences of all
accinia virus-derived peptides, to identify vaccinia-
pecific CTL epitope(s) presented by the six major HLA
lass I supertypes, to determine vaccinia-specific CTL
requency in nonimmune and vaccinated volunteers
sing tetramers of class I-epitope complex, and to
dentify immunodominant CTL epitopes.
A complementary series of studies presented by
lessandro Sette (LIAI) focuses on the identification of
lass I/II restricted epitopes from variola and vaccinia
iruses. The objectives of these ongoing studies are to
1) systematically map responses in humans and HLA
ransgenic mice following vaccinia vaccination, (2) study
rossreactivity with smallpox (variola sequences), and (3)
efine a multiepitope diagnostic set/vaccine construct.
he experiments are again focused on the most com-
on HLA Class I and Class II supertypes covering more
han 99% of the human population. A comprehensive
et of 258 ORFs from WR- (Moss) sequence was
creened by bioinformatic analyses for a total of 7739
redicted peptides. In preliminary studies, a total of 28
2, A11, and B7 potential epitopes in HLA transgenic
ice, and a total of 25 A2, A3, and A1 potential epi-
opes in vaccinated human volunteers have been iden-
ified.
The identification of T cell epitopes of vaccinia virus
n immunized donors is also the focus of the studies
roposed by Clemencia Pinilla of the Torrey Pines Insti-
ute for Molecular Studies. To identity the epitopes
hich elicit optimal CD4 helper and CD8 cytotoxic T
ell immune responses following vaccination, these in-
estigators propose to use a number of human T cell
lones and lines derived from vaccinia immunized hu-
an donors, to screen combinatorial peptide libraries
nd overlapping panels of peptides of pox virus pro-
eins, and to identify epitopes that are responsible for
uman CD4 and CD8 T cell immune responses.
eeting Outcomes
n general, this exciting meeting can be taken as one
f the first signals of the coming of age of the large
cale efforts that have been undertaken to jump start
esearch relating to the immunology and host-pathogen
nteractions for NIAID category A–C priority pathogens
nd emerging diseases. Participants to the meeting be-
ieved that the various Epitope Discovery contracts, the
EDB, and the tools hosted in the Analysis Resource
ave great potential for advancing the development of
iagnostics, immune-based therapeutics and vaccines.
ne clear outcome of the meeting was the determina-
ion of all groups involved to adopt a service orientation
nd to establish and maintain a collaborative relation-
hip with the scientific community. The overall program
epresents a unique opportunity to create a collabora-
ive environment within the various epitope discovery
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161and database teams since the output of these pro-
grams will reside in the IEDB. It is anticipated that dur-
ing the next 5 years, 40,000 to 50,000 epitope entries
will be generated and made available to the scientific
community as a result of the program.
A clear message coming out of the 3-day meeting
was that the field relating to identification and charac-
terization of immune responses is finally moving past
futile discussion on what is the best way (or worse, the
correct way) of identifying epitopes (natural ligands? di-
rect binding? immunogenicity?). Rather, it was recog-
nized that each different method has its own unique
advantages and pitfalls. Most excitingly, the current ini-
tiative will provide epitope data gathered by different,
albeit complementary, approaches and independent re-
search groups. All epitope data will be made available
in the IEDB, presenting an exciting and unique oppor-
tunity for the scientific community to correlate and
integrate data covering different facets of immune re-
sponses. The large amount of data that will be col-
lected and analyzed in the upcoming years will help
define in detail the nature and specificity of immune
responses of humans and nonhuman species to Cate-
gory A–C pathogens. This will represent a unique op-
portunity to understand the interaction of the human
immune system with complex pathogens and also to
understand differences and similarities between the im-
mune responses observed in rodents and humans. The
latter is of great relevance for vaccine development and
design, given the fact that experimental vaccines that
performed well in murine systems have often failed
when tested in humans or nonhuman primates.
Several participants likened the current ongoing ef-
forts to the efforts devoted in the last decade to the
large-scale sequencing of human and pathogen ge-
nomes. In that respect, the accumulation of immune
epitope data will perhaps revolutionize our understand-
ing of immune responses in complex systems. The
work underway will result in the derivation of maps of
immune reactivity and specificity to these complex pa-
thogens at an unprecedented level of thoroughness
and detail. The potential is for an “immunomic” revolu-
tion, mirroring the proteomic and genomic ones. These
efforts have great strategic potential because it is antic-
ipated that they will be closely integrated with other
initiatives covering different aspects of A–C pathogens
research, such as genomics, vaccine and adjuvant de-
velopments, genetic responsiveness to vaccines, diag-
nostic, clinical trials databases, and the like. The cur-
rent project will participate in and increase contribution
of data, facilitate tool development and utilization, and
in general, participate in larger data integration initia-
tives at NIH/NIAID. Finally, it is expected that the re-
sults, techniques, and bioinformatics tools and data-
bases created under the auspices of the project will be
of general applicability and thus benefit the immuno-
logical and scientific community as a whole.
In the closing discussion session, several groups
voiced the opinion that it will be important to standard-
ize data generation, transfer formats, and protocols. Of
immediate concern is to ensure that the database
schema correctly captures the data concepts utilized
from the discovery groups. Beyond this immediate ne-
cessity, it was felt that in the previous years much waslearned by the experience of groups working on stand-
ardizing methods and procedures for tissue typing on
one hand, and clinical testing and data reporting, espe-
cially in the context of vaccine trial networks sponsored
from the NIH NIAID and AIDS divisions, on the other
hand. The group expressed its determination to incor-
porate lessons learned from these experiences in the
current program. The next meeting of the fourteen epi-
tope discovery groups and the IEDB team will be early
November 2005.
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